Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 9/20 | 0.73 |
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19148563 | 0.90 | RORC (0.67) | RORCMAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL6816172 | 0.90 | MAPT (0.71) | RORCMAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL15668418 | 0.88 | RORC (0.68) | RORCMAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL19148582 | 0.86 | RORC (0.61) | RORCMAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7814934 | 0.86 | RORC (0.62) | RORCMAPTSMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL18146474 | 0.85 | RORC (1.00) | RORCMAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7130662 | 0.84 | RORC (0.73) | RORCMAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL25346243 | 0.82 | RORC (0.60) | RORCMAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL8042285 | 0.82 | MAPT (0.62) | RORCMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6811868 | 0.82 | MAPT (0.64) | RORCMAPTSMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399966-B2 | Compounds for treatment of trypanosomes and neurological pathogens and uses thereof | UNIVERSITY OF WASHINGTON (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399966-B2 | Compounds for treatment of trypanosomes and neurological pathogens and uses thereof | UNIVERSITY OF WASHINGTON (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190031649-A1 | COMPOUNDS FOR TREATMENT OF TRYPANOSOMES AND NEUROLOGICAL PATHOGENS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2019-01-31 | — | — | US | disclosed |
| US-20190031649-A1 | COMPOUNDS FOR TREATMENT OF TRYPANOSOMES AND NEUROLOGICAL PATHOGENS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2019-01-31 | — | — | US | disclosed |
| WO-2017127627-A1 | COMPOUNDS FOR TREATMENT OF TRYPANOSOMES AND NEUROLOGICAL PATHOGENS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-07-27 | — | — | WO | disclosed |
| WO-2017127627-A1 | COMPOUNDS FOR TREATMENT OF TRYPANOSOMES AND NEUROLOGICAL PATHOGENS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-07-27 | — | — | WO | disclosed |
| EP-1957461-B1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH INC (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8101610-B2 | Blocking signals; anticancer agents | GENENTECH, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080269215-A1 | Bisamide Inhibitors of Hedgehog Signaling | GENENTECH INC. (US) | 2008-10-30 | — | — | US | disclosed |
| EP-1957461-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | Genentech, Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007059157-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031649-A1 | COMPOUNDS FOR TREATMENT OF TRYPANOSOMES AND NEUROLOGICAL PATHOGENS AND USES THEREOF | TSPO, GBA1, NLN | RORC 3572/4885MAPT 364/4885SMN1; SMN2 361/4885 |
| US-10399966-B2 | Compounds for treatment of trypanosomes and neurological pathogens and uses thereof | TSPO, GBA1, NLN | RORC 3572/4885MAPT 364/4885SMN1; SMN2 361/4885 |
| US-20080269215-A1 | Bisamide Inhibitors of Hedgehog Signaling | SHH, GLI1, SMO | RORC 872/4885MAPT 2726/4885SMN1; SMN2 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.